IRCT20200525047562N1
Recruiting
Phase 3
Immediate uses of convalescent covid-19 plasma in the treatment of new infected patients at the first day of hospitalization in a clinical trail
High Educational and Research Institute of Transfusion Medicine0 sites100 target enrollmentTBD
ConditionsCOVID-19 disease.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19 disease.
- Sponsor
- High Educational and Research Institute of Transfusion Medicine
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Symptomatic COVID\-19 patients who are hospitalized and have Score\>4 in terms of WHO Progression Scale.
- •The least reasons of hospitalization are dyspnea and/or SPO2\<93% or RR\>30
- •The intervention should be performed within the first 24 hours of hospitalization.
Exclusion Criteria
- •COVID\-19 patients having Score\<4 in terms of WHO Progression Scale.
- •More than 24 hours passed from hospitalization.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
se of Convalescent Plasma in the treatment of COVID-19IRCT20200414047072N1Hilton Pharma Pvt. Ltd.357
Recruiting
Phase 2
Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patientsIRCT20200406046968N2Tabriz University of Medical Sciences30
Not yet recruiting
Not Applicable
Vaccine Plasma for the Treatment of COVID-19 InfectioCOVID-19SARS-CoV-2C01.748.214RBR-2ggx7smMinistério da Ciência, Tecnologia e Inovações
Active, not recruiting
Not Applicable
"NORPLASMA" Covid-19 Convalescent Plasma Treatment Monitoring StudyCOVIDNCT04463823Oslo University Hospital500
Active, not recruiting
Phase 2
sing blood plasma to develop passive immunity to coronavirus in EcuadorISRCTN85216856niversidad Tecnológica Equinoccial200